Newsfeeds - Spark Newswire

1 minute read

Kezar Life Shares Shoot Higher After Positive Results From Mid-Stage Study Of Kidney Disease Candidate

Today, 7:06 AM

Kezar Life Sciences, Inc. (NASDAQ: KZR) reported positive topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib in patients with active lupus nephritis (LN).

KZR

1 minute read

After-Hours Action: Why Kezar Life Sciences Stock Is Soaring

By Adam Eckert

Today, 7:06 AM

Kezar Life Sciences Inc (NASDAQ: KZR) shares are surging in Monday's after-hours session after the company announced topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib.

KZR

24 minute read

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

Today, 7:06 AM

On Friday, 422 stocks made new 52-week lows.

AAT

3 minute read

The Week Ahead In Biotech (May 30-June 4): FDA Decision For Eton’s Partnered Epilepsy Drug, ASCO Conference Gets Underway And More

By Shanthi Rexaline

Today, 7:06 AM

Biotech stocks advanced in the week ended May 27, tracking the overall positive sentiment of the broader market. Notwithstanding the week's strength, the sector has been one of the worst performers for the year-to-date period.

ABBV

6 minute read

81 Biggest Movers From Yesterday

By Lisa Levin

Today, 7:06 AM

Gainers Rail Vision Ltd. (NASDAQ: RVSN) shares climbed 62.4% to close at $2.16 on Wednesday after gaining around 5% on Tuesday.

ACON

3 minute read

Mid-Afternoon Market Update: Crude Oil Jumps 5%; Fed Boosts Interest Rates By 0.5%

By Lisa Levin

Today, 7:06 AM

U.S. stocks traded mixed toward the end of trading, after the Federal Reserve announced its policy decision.

AMRN

5 minute read

58 Biggest Movers From Yesterday

By Lisa Levin

Today, 7:06 AM

Gainers

ADBE

3 minute read

38 Stocks Moving In Wednesday’s Mid-Day Session

By Lisa Levin

Today, 7:06 AM

Gainers

ADBE

1 minute read

Here’s Why Kezar Life Sciences Shares Are Moving

By Henry Khederian

Today, 7:06 AM

Kezar Life Sciences Inc (NASDAQ: KZR) shares are trading higher by 5.0% at $16.08 after HC Wainwright & Co. maintained a Buy rating on the stock and raised its price target from $20 to $22.

KZR

1 minute read

HC Wainwright & Co. Maintains Buy on Kezar Life Sciences, Raises Price Target to $22

By Benzinga Newsdesk

Today, 7:06 AM

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Kezar Life Sciences (NASDAQ:KZR) with a Buy and raises the price target from $20 to $22.

KZR